The early market access vehicle – An innovative demand-driven model to catalyse introduction of new optimal health products in low- and middle-income countries

IF 1.7 Q3 HEALTH CARE SCIENCES & SERVICES
Ademola Osigbesan , Ikechukwu Amamilo , Aayush Solanki , Robert Matiru , James Conroy , Alya Omar , Karin Hatzold , Carolyn Amole , Kehinde Onasanya , Janet Ginnard
{"title":"The early market access vehicle – An innovative demand-driven model to catalyse introduction of new optimal health products in low- and middle-income countries","authors":"Ademola Osigbesan ,&nbsp;Ikechukwu Amamilo ,&nbsp;Aayush Solanki ,&nbsp;Robert Matiru ,&nbsp;James Conroy ,&nbsp;Alya Omar ,&nbsp;Karin Hatzold ,&nbsp;Carolyn Amole ,&nbsp;Kehinde Onasanya ,&nbsp;Janet Ginnard","doi":"10.1016/j.hpopen.2024.100135","DOIUrl":null,"url":null,"abstract":"<div><div>Low-and middle-income countries (LMICs) account for a significant proportion of the burden of disease for communicable illnesses globally; with malaria, tuberculosis (TB), and HIV/AIDS being the leading causes of death. Despite this disparity, LMICs often have limited or delayed access to newer optimal health products compared to high-income countries (HICs). This limitation in access, driven by a myriad of barriers, undermines the potential health benefits that could be gained in LMICs through the introduction of better health products. To improve this inequity, governments in HICs, non-governmental organizations, and pharmaceutical companies, often resort to establishing donation programs for LMICs, to circumvent some of the access barriers. While well-implemented donation programs have the potential to improve access to new products, poorly executed donation programmes are common. These often have negative effects such as: overreliance on donations by recipient countries, <em>dumping</em> of short-dated or unwanted products, costs of waste disposal where unsuitable or excess products are received, and a lack of focus on access sustainability planning. Unitaid’s early market access vehicle (EMAV) is an innovative demand-driven access model for introducing new optimal health commodities in LMICs. An EMAV entails a conditional purchase commitment to the manufacturer for a defined quantity of selected products in exchange for a set of access commitments, required to facilitate equitable access in the target markets. EMAVs are designed to link catalytic donations to pathways for sustainable access. Unitaid, in collaboration with its partners, has leveraged the EMAV to introduce two innovative health products in a number of LMICs. This article discusses the EMAV model and builds the case on why stakeholders working on new product access should consider this approach as an alternative to traditional donation programmes.</div></div>","PeriodicalId":34527,"journal":{"name":"Health Policy Open","volume":"8 ","pages":"Article 100135"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Policy Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590229624000200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Low-and middle-income countries (LMICs) account for a significant proportion of the burden of disease for communicable illnesses globally; with malaria, tuberculosis (TB), and HIV/AIDS being the leading causes of death. Despite this disparity, LMICs often have limited or delayed access to newer optimal health products compared to high-income countries (HICs). This limitation in access, driven by a myriad of barriers, undermines the potential health benefits that could be gained in LMICs through the introduction of better health products. To improve this inequity, governments in HICs, non-governmental organizations, and pharmaceutical companies, often resort to establishing donation programs for LMICs, to circumvent some of the access barriers. While well-implemented donation programs have the potential to improve access to new products, poorly executed donation programmes are common. These often have negative effects such as: overreliance on donations by recipient countries, dumping of short-dated or unwanted products, costs of waste disposal where unsuitable or excess products are received, and a lack of focus on access sustainability planning. Unitaid’s early market access vehicle (EMAV) is an innovative demand-driven access model for introducing new optimal health commodities in LMICs. An EMAV entails a conditional purchase commitment to the manufacturer for a defined quantity of selected products in exchange for a set of access commitments, required to facilitate equitable access in the target markets. EMAVs are designed to link catalytic donations to pathways for sustainable access. Unitaid, in collaboration with its partners, has leveraged the EMAV to introduce two innovative health products in a number of LMICs. This article discusses the EMAV model and builds the case on why stakeholders working on new product access should consider this approach as an alternative to traditional donation programmes.
早期市场准入工具——一种创新的需求驱动模式,促进在低收入和中等收入国家引进新的最佳保健产品。
低收入和中等收入国家(LMICs)在全球传染病疾病负担中占很大比例;疟疾、结核病和艾滋病毒/艾滋病是导致死亡的主要原因。尽管存在这种差异,与高收入国家相比,中低收入国家获得更新的最佳保健产品的机会往往有限或延迟。这种由无数障碍造成的获取方面的限制,破坏了中低收入国家通过引进更好的保健产品可能获得的潜在健康效益。为了改善这种不平等现象,高收入国家的政府、非政府组织和制药公司往往采取为中低收入国家建立捐赠计划的办法,以规避一些获取障碍。虽然执行良好的捐赠计划有可能改善获得新产品的机会,但执行不良的捐赠计划很常见。这些往往会产生负面影响,例如:过度依赖受援国的捐赠,倾销短期或不需要的产品,在接收不合适或过量产品时处理废物的成本,以及缺乏对可持续性规划的关注。国际药品采购机制的早期市场准入工具(EMAV)是一种创新的需求驱动的准入模式,用于在中低收入国家引进新的最佳卫生商品。EMAV要求制造商有条件地购买一定数量的选定产品,以换取一套准入承诺,这是促进目标市场公平准入所必需的。emav旨在将催化捐赠与可持续获取途径联系起来。Unitaid与其合作伙伴合作,利用EMAV在一些中低收入国家引进了两种创新保健产品。本文讨论了EMAV模型,并构建了为什么致力于新产品获取的利益相关者应该考虑将这种方法作为传统捐赠计划的替代方案的案例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Health Policy Open
Health Policy Open Medicine-Health Policy
CiteScore
3.80
自引率
0.00%
发文量
21
审稿时长
40 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信